Oncolytics Biotech (ONCY) Change in Accured Expenses (2020 - 2021)
Oncolytics Biotech's (ONCY) quarterly Change in Accured Expenses came in at $752218.2 in Q3 2021, little changed year-over-year from $753854.6 in Q3 2020, and little changed quarter-over-quarter from $753854.6 in Q3 2020.
Powered by 
Analysis
Oncolytics Biotech (ONCY) Change in Accured Expenses (2020 - 2021) Analysis & Trends
Oncolytics Biotech (ONCY) has reported Change in Accured Expenses for 2 consecutive years, with $752218.2 the latest figure, recorded in Q3 2021.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Accured Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn | 852.00 Mn |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn | 338.00 Mn |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn | 222.50 Mn |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn | 492.70 Mn |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn | - |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn | 11.00 Mn |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn | 61.62 Mn |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn | -49.70 Mn |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn | -13.91 Mn |
| 10 | Oncolytics Biotech | 91.92 Mn | 91.92 Mn | - | - |